GlassScriptPhysician profile
Albert Enow Takem
NPI 1437414455
$5,561.06
in general payments reported to CMS, 2019-2025
38 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.74 · 2020: $73.60 · 2021: $655 · 2022: $723 · 2023: $1,296 · 2024: $1,567 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,051.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,001.54 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $856.44 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $617.81 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $472.04 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $270.30 | 2021-2022 | |
| Pfizer INC. | $266.00 | 2019-2025 | |
| Amgen INC. | $259.38 | 2024-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.70 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $138.44 | 2024 | Eliquis |
| Abbott Laboratories | $124.10 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $120.74 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $118.76 | 2021 | |
| Medtronic, INC. | $95.78 | 2025 | Inceptiv |
| Gilead Sciences, INC. | $95.04 | 2024-2025 | |
| Astellas Pharma US INC | $89.91 | 2023-2025 | Veozah |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Takem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.